Drug Type Oncolytic virus |
Synonyms Ad5/3-E2F-d24-hTNFa-IRES-hIL2, TILT 123, TILT-123 |
Target |
Action inhibitors |
Mechanism IL-2 inhibitors(Interleukin-2 inhibitors), TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Platinum-Resistant Fallopian Tube Carcinoma | Phase 2 | United States | 17 May 2022 | |
Platinum-Resistant Fallopian Tube Carcinoma | Phase 2 | Finland | 17 May 2022 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | United States | 17 May 2022 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | Finland | 17 May 2022 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 2 | United States | 17 May 2022 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 2 | Finland | 17 May 2022 | |
Platinum-Sensitive Fallopian Tube Carcinoma | Phase 2 | United States | 17 May 2022 | |
Platinum-Sensitive Fallopian Tube Carcinoma | Phase 2 | Finland | 17 May 2022 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 2 | United States | 17 May 2022 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 2 | Finland | 17 May 2022 |
Phase 1 | 52 | TILT-123 3 × 10^9 VP | awtalmxxiq(dhrpepzljo) = uzoebepaov bdstqqzjfp (zrlgznmqnz ) | Positive | 06 Nov 2024 | ||
TILT-123 4 × 10^12 VP | awtalmxxiq(dhrpepzljo) = nidgxleaep bdstqqzjfp (zrlgznmqnz ) | ||||||
Phase 1 | 14 | xswelzpfuv(shtuamndmi) = Frequent grade 1-4 treatment-related AEs (>30% of patients) were anemia, nausea, lymphocyte count decreased, fever and diarrhea ujilypivvi (asevtrzifi ) | Positive | 24 May 2024 | |||
Phase 1 | 52 | dlrzgzpwvj(oymglablwp) = increased in the patients´ serum cpiicfdwtm (gesnevwzhl ) | Positive | 24 May 2024 | |||
NCT05271318 (AACR2024) Manual | Phase 1 | 15 | lzoidezqee(ltablrlsxa) = not observed byzdtuyimh (cyzewaskju ) View more | Positive | 05 Apr 2024 | ||
Phase 1 | 20 | mfomlbugcz(cfjvrwbsby) = rdzmhafbub ohztuegnuq (wkssgcgzhu ) | Positive | 28 Mar 2024 | |||
Phase 1 | 16 | zqrszqqadj(kjkrkcuhon) = The most frequently reported adverse events (AEs) related to TILT-123 were fever (63%) and pain at the injection site (44%) while most frequent AEs related to TIL therapy were fever (50%) and chills (24%). rsxrxdters (wsgbaetvon ) | Positive | 06 Dec 2023 | |||
Phase 1 | 20 | ymgwkcjeeg(oaznsrqbtk) = not observed ltnqajluxp (hduseukxhb ) View more | Positive | 31 Oct 2023 | |||
Phase 1 | 18 | mhxufgdftk(cogwvecxml) = hcvflewnhf kbwuqhcalx (fdwqixzauf ) | Positive | 01 Nov 2022 |